Navigation Links
PSA Test Cut-off Could Signal Low-Risk Prostate Cancer

By Amanda Gardner
HealthDay Reporter

TUESDAY, Feb. 15 (HealthDay News) -- Men who have a low prostate-specific antigen (PSA) score when they're first tested may not need to be screened annually and probably don't need to undergo a biopsy, a new study suggests.

Dutch researchers presenting the findings at the Genitourinary Cancers Symposium in Orlando, Fla., said that few men with a PSA below 3.0 ng/ml were likely to develop prostate cancer and die of the disease.

"PSA can identify those at low risk of prostate cancer and once you have done that, you can remove almost 50 percent of men in the age group 55 to 74 [from undergoing biopsies]," said study senior author Monique Roobol, an epidemiologist in the department of urology at Erasmus University Medical Center in Rotterdam.

For this study, about 20,000 men aged 55 to 74 in the Rotterdam area were screened, with those having PSA scores at or above the cut-off of 3.0 sent for biopsies and additional screenings every four years. Eighty percent of men in the group had PSA levels below that threshold.

In this group of men, the higher the PSA level at baseline, the more likely the person was to develop prostate cancer and to die of the disease. Only 1.8 percent of men with PSA scores below 1.0 were diagnosed with prostate cancer, with only 0.04 percent dying of the disease. This compares with 15.7 percent of those with scores from 2 percent to 2.9 percent developing a malignancy and 0.36 percent dying of the disease.

"This gives us some confidence that annual PSA screening is going to soon become a thing of the past," said Dr. Nicholas J. Vogelzang, chair of the Developmental Therapeutics Committee of US Oncology, who moderated the teleconference. "A low PSA, particularly those in men who have less than 1.0, and probably those less than 2.0, certainly could be considered for substantially longer intervals of PSA screening... Personalization of PSA screening is clearly underway."

A second study also being presented at the symposium found that a drug already used to treat enlarged prostate gland may delay the progression of low-risk, early prostate cancer among men who choose a wait-and-see approach to treatment.

In comparison to men with low-risk, early-stage prostate cancer who took a placebo, "men randomized to receive Avodart saw their chance of progression significantly reduced, by approximately 40 percent," said study author Dr. Neil Fleshner, head of urology at the University Health Network and Love Chair in Prostate Cancer Prevention at Princess Margaret Hospital, both in Toronto. "Men with low-risk prostate cancer who want to have a period of observation should consider using this drug."

But the maker of Avodart (dutasteride), GlaxoSmithKline, is unlikely to apply for new approval to market the drug for what is essentially prevention, meaning it would be used off-label in this context, he added.

A final study of almost 4,000 patients found that surgeons needed to perform 1,600 procedures known as robotic-assisted laparoscopic radical prostatectomies (RALP) to become adept at the procedure. In comparison with typical laparoscopic surgery, RALP offers surgeons three-dimensional vision and such improvements as better magnification and hand tremor filtering.

"We recommend that this operation should not be done by all urologists in small community hospitals but should be focused and concentrated on high volume centers of excellence... in order to achieve best possible results for patients," said study author Dr. Prasanna Sooriakumaran, a visiting fellow in urology at the Weill Cornell Medical College in New York.

"The procedure is not as easy as manufacturers make it out to be, and enthusiasm in the U.S. needs to be tempered in terms of which hospitals should be buying the equipment and which surgeons should be doing these sorts of operations," he added.

One caution, though, is that the study only looked at three surgeons performing RALP.

More information

The National Cancer Institute has more on prostate cancer.

SOURCES: Feb. 15, 2011, teleconference with: Nicholas J. Vogelzang, M.D., chair and medical director, Developmental Therapeutics Committee, US Oncology; Monique Roobol, Ph.D., epidemiologist, department of urology, Erasmus University Medical Center, Rotterdam, the Netherlands; Neil Fleshner, M.D., head, urology, University Health Network and Love Chair in Prostate Cancer Prevention, Princess Margaret Hospital, Toronto; Prasanna Sooriakumaran, M.D., Ph.D., visiting fellow, urology, Weill Cornell Medical College, New York City; Feb. 15-17, 2011, presentations, Genitourinary Cancers Symposium, Orlando, Fla.

Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Premature Death Could Await Obese Kids
2. Six Other E. colis Could Be Lurking In Your Valentine Days Dinner
3. Tiny fruit fly could offer big clues in fight against obesity, researcher says
4. New Book Reveals How Qigong Could Be The Eastern Answer To Botox
5. Chocolate lovers could be lowering their risk of stroke: Study
6. Charging less for more effective treatments could reduce health care costs while improving health
7. Clinical trial underway: Miniature ultrasound device could revolutionize pain relief
8. UAB-led study shows simple steps could reduce stillbirths by up to 1 million
9. Most maternal deaths in sub-Saharan Africa could be avoided
10. Dolphins could be ideal model to study human cervical cancer, UF veterinarians say
11. New Technology Could Widen Reach of Vaccines
Post Your Comments:
Related Image:
PSA Test Cut-off Could Signal Low-Risk Prostate Cancer
(Date:11/26/2015)... (PRWEB) , ... November 26, 2015 , ... ... a real-time eReferral system for diagnostic imaging in the Waterloo region. Using the ... and Nuclear Medicine tests directly from their electronic medical record (EMR) without the ...
(Date:11/26/2015)... ... November 26, 2015 , ... The Catalent ... and the need to integrate dose form selection in early phase drug development. ... membership organization supporting and bringing together the UK’s emerging life sciences companies, corporate ...
(Date:11/26/2015)... ... 2015 , ... PRMA Plastic Surgery is updating their record books yet again ... free flap breast reconstruction surgery! , “What an accomplishment for the PRMA team, says ... and it’s an honor to have served all of these women.” , PRMA is ...
(Date:11/26/2015)... ... November 26, 2015 , ... Pixel Film Studios brings ... with ProTrailer: Vintage. This newly styled ProTrailer pack comes with 30 all-new vintage-inspired ... font, giving users limitless opportunities to stylize and create designs quickly and easily, ...
(Date:11/26/2015)... ... November 26, 2015 , ... Indosoft Inc., developer and distributor ... application server to improve system efficiency and reliability. , The new Q-Suite 6 platform ... standards, the system avoids locking itself into a specific piece of software for many ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... Países Bajos, November 26, 2015 ... fotodinámica de Bremachlorin para el cáncer avanzado.   ... con la terapia fotodinámica de Bremachlorin para el cáncer ... enfoque combina la inmunoterapia con la terapia fotodinámica de ... Clinical Cancer Research . --> Clinical Cancer ...
(Date:11/26/2015)... 26, 2015 ... aanpak combineert immunotherapie met Bremachlorin-photodynamische therapie voor ... ) --> ... ) Uit ... Centrum (LUMC) blijkt ...
(Date:11/26/2015)... 2015 3D bioprinting market is ... a new report by Grand View Research Inc. Rising prevalence ... demands kidney transplantation is expected to boost the market growth, ... organ transplantation. --> 3D bioprinting market is ... a new report by Grand View Research Inc. Rising prevalence ...
Breaking Medicine Technology: